Table 2.
Comparison of demographic data between EPS group and non-EPS group
| Demographic data | EPS group (n=204) |
Non-EPS group (n=475) |
Statistics | Significant (P values) |
| Age | 40.8 (16.8) | 37.3 (14.0) | t=−2.61 | 0.01** |
| Gender (female) | 104 (50.7%) | 204 (42.9%) | X2=3.72 | 0.054 |
| Age of onset | 25.1 (9.3) | 25.5 (9.0) | t=0.76 | 0.446 |
| Illness duration | 15.8 (12.1) | 11.7 (12.1) | Z=3.41 | 0.001*** |
| Years since first prescribed antipsychotics | 10.6 (12.0) | 14.4 (15.2) | Z=3.1 | 0.002 |
| High D2 receptor antagonistic effect antipsychotics | 95 (44.6%) | 185 (38.9%) | X2=3.42 | 0.064 |
| Low and medium D2 receptor antagonistic effect antipsychotics | 109 (53.4%) | 290 (61.1%) | ||
| Atypical antipsychotics monotherapy | 114 (55.9%) | 313 (65.9%) | ||
| Atypical antipsychotics polytherapy | 72 (35.3%) | 141 (29.7%) | X2=8.52 | 0.014* |
| Typical antipsychotics and atypical antipsychotics polytherapy | 18 (8.8%) | 21 (4.4%) | ||
| Mood stabiliser | 18 (8.8%) | 22 (4.6%) | X2=4.52 | 0.033* |
| Antidepressants | 12 (5.9%） | 24 (5.1%) | X2=0.196 | 0.658 |
*p≤0.0; **p≤0.001; ***p≤0.0.
EPS, extrapyramidal symptoms.